Please assess the completion status of the following clinical trial:

Trial Title: Two-Part, Open-Label, Multi-Center, Phase 1/2 Study of BIW-8962 as Monotherapy in Subjects With Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Phase 1: histopathological-documented, measurable or non-measurable unresectable, advanced primary or recurrent SCLC, NSCLC or mesothelioma~* Phase 2: measurable, unresectable advanced or recurrent SCLC~* A life expectancy \> 3 months~* Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1 at study entry~* Echocardiogram or multigated acquisition (MUGA) scan with left ventricular ejection fraction (LVEF) ≥ 50%, or ≥ institution's established lower limit of normal~* Adequate hematologic, hepatic, renal and lung function~Exclusion Criteria:~* Subject received cytotoxic anti-cancer chemotherapy, orally available signaling pathway-targeted therapy, hormonal therapy, radiotherapy, immunotherapy, or investigational agents within 3 weeks prior to the first dose~* Subject received monoclonal antibodies within 4 weeks of the first dose~* Major surgery within 4 weeks prior to the first dose~* Known symptomatic brain metastases~* Clinically significant cardiovascular disease~* Leptomeningeal disease~* Uncontrolled intercurrent illness including ongoing or active infection, uncontrolled diabetes, etc~* Known HIV disease or acquired immunodeficiency syndrome-related illness~* A psychiatric illness, disability or social situation~* Hypersensitivity reaction to monoclonal antibodies, other therapeutic proteins~* A history of primary brain/CNS malignancy~* Neurological paraneoplastic syndrome

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BIW-8962 (Type: EXPERIMENTAL): Phase 1 - Dose escalation based on the BIW-8962 tolerability and safety data obtained from three subjects enrolled in a cohort (first cycle of treatment), enrollment at the next dose level or additional subjects into the ongoing cohort will occur~Phase 2 - Recommended dose determined in Phase 1

Based on this trial design, predict the completion outcome and termination type (if applicable).